PharmTech Drug Digest 11.20
News|Articles|October 3, 2014

Lucideon Plans to Expand Headquarters

Lucideon announced that it is investing £1.5 million to expand its headquarters to include pharmaceutical quality-control testing laboratories.

Lucideon, a global provider of materials-development technologies, testing, resource efficiency, and assurance, announced that it plans to invest £1.5 million ($2.4 million USD) to expand its headquarters in Stoke-on-Trent, England to include pharmaceutical quality-control testing laboratories.

The facilities include chemistry and microbiology laboratories for pharamcopeial testing (British Pharmacopoeia, European Pharmacopoeia, United States Pharmacopeia, and Japanese Pharacopoeia), quality control (batch release) testing, method development and validation, raw material analysis, stability storage and water testing, and microbiology determination testing including sterility, endotoxin, and bioburden.

Source: Lucideon


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.